filterlex
EMBOLIC PROTECTION

FILTERLEX - Full-Body Embolic Protection Device for TAVI

AT A GLANCE

IP: PCT submitted in Sep. 2016, received exceptionally positive search report and written opinion

Status: Pre-clinical

UNIQUE FEATURES

- Provides full-body embolic protection
- No additional arterial access required
- Performs deflection, capture and removal of embolic particles
- Easy and intuitive deployment and retrieval
- Protects aorta surface
- Stable and safe device anchoring
- No interference to procedure devices
- Applicable for a variety of procedures

THE MARKET

The worldwide TAVI market is estimated to surpass $5.5B by 2020. Additional major markets include TMVR (estimated at five times of the TAVI market) and AF Ablation (1.2M procedures annually). The total addressable market for Filterlex is valued at over $5B.

Filterlex Medical Ltd. was founded in June 2015 to develop a novel, full-body embolic protection device to reduce the risk of stroke and related embolic complications during left-heart interventional procedures.

THE NEED

During catheter-based, left-heart procedures such as TAVI, embolic particles are often released to the blood flow. Particles migration to the brain may cause a spectrum of neurological deficiencies, from cognitive impairment to debilitating stroke. Emboli released to distal organs may result in acute kidney injury and ischemia.

THE PRODUCT

The Filterlex device is a next-generation full-body embolic protection device, easily and intuitively deployed and retrieved. The device is securely positioned in the aorta, protects its surface while facilitating a seamless TAVI procedure. Its distinctive, triple action design provides a full-body embolic protection by deflecting, capturing and removing embolic particles. Uniquely, it requires no additional arterial access and does not interfere to the procedure workflow.

THE COMPETITION

Claret Medical – Sentinel, overall funding estimate - $41M.
FDA clearance 510k De-novo in June 2017, CE since Jan. 2014.
Keystone Heart – TriGuard, overall funding estimate - $25M.
FDA, 510K, undergoing IDE trial, CE since Sept. 2013.
ICS – Emblok, early clinical-stage.
Protembis – ProtEmbo, early clinical-stage.

THE TEAM

Ms. Sigal Eli - CEO: Entrepreneur, inventor and interventional cardiology imaging expert with extensive experience in TAVI procedures, a former clinical and training specialist at a medical imaging company.

Mr. Eyal Teichman - CTO: Entrepreneur, mechanical engineer and CTO with over 25 years of R&D experience with extensive experience in implantable devices in the cardiovascular field.

Giora Weisz, M.D. - Chairman of Advisory Board: Director of Interventional Cardiology at Montefiore Medical Center, and faculty of the Cardiovascular Research Foundation in New York, NY.

Mr. Ron Davidson – Active Board Member: Seasoned executive with 20 years' experience in managing and accelerating companies in the healthcare field, led two companies to successful exits.

Dr. Shimon Eckhouse – Chairman: Founder and investor of numerous medical technology firms. One of Israel's leading medical entrepreneur and the owner and Active Chairman of Alon MedTech Ventures incubator.

Contact: Sigal Eli – CEO | sigal@filterlex.com | +972-54-669-5900 | www.filterlex.com